Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Syndax Pharmaceuticals' Non-Current Debt history runs 4 years deep, the most recent figure standing at $331.6 million for Q4 2024.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $331.6 million in Q4 2024; TTM through Dec 2024 was $331.6 million, a N/A change from a year earlier, with the FY2024 full-year figure at $331.6 million, changed N/A from the prior year.
• Non-Current Debt advanced to $331.6 million in Q4 2024 per SNDX's latest filing, from $13.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $331.6 million in Q4 2024 and bottomed at $11.0 million in Q3 2021.
• The 4-year median for Non-Current Debt is $17.8 million (2020), against an average of $45.3 million.
• Biggest YoY gain for Non-Current Debt was 11.56% in 2021; the steepest drop was 45.07% in 2021.
• Year by year, Non-Current Debt stood at $17.8 million in 2020, then rose by 11.56% to $19.9 million in 2021, then plunged by 34.69% to $13.0 million in 2022, then jumped by 2451.68% to $331.6 million in 2024.
• Per Business Quant, the three latest SNDX Non-Current Debt figures stand at $331.6 million (Q4 2024), $13.0 million (Q2 2022), and $16.5 million (Q1 2022).